engleski

IL-6-174 C/G polymorphism in the gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

IL-6 is a pleiotropic cytokine with still controversial role in carcinogenesis of different cancer types. Its promoter SNP -174 G/C is the most studied polymorphism associated with increased IL-6 transcription and serum levels. The knowledge of the role of IL-6 polymorphisms and IL-6 serum values and their correlation in the gastroenteropancratic neuroendocrine tumors is lacking. We investigated for the first time frequencies of IL-6 -174 polymorphisms in 80 GEP-NET patients and 162 age and sex-matched healthy controls, serum values of IL-6 in patients with GEP-NET and their correlation with high expression GC and GG -174 polymorphisms. To analyze IL6 -174 C/G polymorphism PCR – NlaIII RFLP method was used, and serum levels were measured automatically on Immulite analyzer by enzymatic solid-phase chemiluminescent immunometric method (DPC, Los Angeles, CA). Normal levels were lower than 5.9 pg/ml. Genotype differences between patients and healthy controls as well as between patients with gastrointestinal and pancreatic neuroendocrine tumors (PET) and functional and non-functional PETs were tested by χ 2 test and Fisher’ s Exact test. Analysis of variance (ANOVA with proc GLM in SAS/Stat) was performed for the group comparison. Level of significance was  =0.05. High expression IL-6 -174 (GC and GG) polymorphisms were significantly more frequent among patients with non-functional PETs (p=0.0289) and serum IL-6 values correlated signifficantly with G allele at the -174 position in the promoter region of the IL-6 gene (p=0.0139).

IL6 -174 SNP; GEP-NETs; Il-6; -174 g/c promoter snp; Gep-net; PET

nije evidentirano